MA61888B1 - Compositions, procédés et systèmes pour l'administration de médicament en aérosol - Google Patents

Compositions, procédés et systèmes pour l'administration de médicament en aérosol

Info

Publication number
MA61888B1
MA61888B1 MA61888A MA61888A MA61888B1 MA 61888 B1 MA61888 B1 MA 61888B1 MA 61888 A MA61888 A MA 61888A MA 61888 A MA61888 A MA 61888A MA 61888 B1 MA61888 B1 MA 61888B1
Authority
MA
Morocco
Prior art keywords
compositions
systems
methods
drug delivery
acting
Prior art date
Application number
MA61888A
Other languages
English (en)
Inventor
David Lechuga-Ballesteros
Vidya JOSHI
James ARCHBELL
Kellisa LACHACZ
Charina LAMPA
Lauren MELLO
Gertrude GUTIERREZ
Penny Tan
Michael Riebe
Original Assignee
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=82748203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA61888(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Pharmaceuticals Lp filed Critical Astrazeneca Pharmaceuticals Lp
Publication of MA61888B1 publication Critical patent/MA61888B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions, des procédés et des systèmes pour l'administration pulmonaire d'agents actifs via un inhalateur-doseur. Dans certains modes de réalisation, les compositions comprennent un milieu de suspension HFO-1234ze(E), des particules d'agent actif et des particules de suspension. Les particules d'agent actif peuvent comprendre un, deux, trois ou quatre agents actifs choisis parmi un antagoniste muscarinique à action prolongée (LAMA), un agoniste β2 à action prolongée (LABA), un agoniste bêta à action brève (SABA). ), un corticostéroïde inhalé (CSI) et un agent anti-inflammatoire non corticostéroïde.
MA61888A 2021-07-09 2022-07-08 Compositions, procédés et systèmes pour l'administration de médicament en aérosol MA61888B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220362P 2021-07-09 2021-07-09
US202163282356P 2021-11-23 2021-11-23
EP23155432.0A EP4197528B1 (fr) 2021-07-09 2022-07-08 Compositions, procédés et systèmes pour l'administration de médicament en aérosol

Publications (1)

Publication Number Publication Date
MA61888B1 true MA61888B1 (fr) 2024-06-28

Family

ID=82748203

Family Applications (3)

Application Number Title Priority Date Filing Date
MA61888A MA61888B1 (fr) 2021-07-09 2022-07-08 Compositions, procédés et systèmes pour l'administration de médicament en aérosol
MA60223A MA60223B1 (fr) 2021-07-09 2022-07-08 Compositions, procédés et systèmes pour l'administration d'un médicament en aérosol
MA60224A MA60224B1 (fr) 2021-07-09 2022-07-08 Compositions, méthodes et systèmes pour l'administration d'un médicament en aérosol

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA60223A MA60223B1 (fr) 2021-07-09 2022-07-08 Compositions, procédés et systèmes pour l'administration d'un médicament en aérosol
MA60224A MA60224B1 (fr) 2021-07-09 2022-07-08 Compositions, méthodes et systèmes pour l'administration d'un médicament en aérosol

Country Status (28)

Country Link
US (5) US20230026203A1 (fr)
EP (6) EP4197528B1 (fr)
JP (3) JP2024527348A (fr)
KR (3) KR20240042436A (fr)
AU (3) AU2022308837A1 (fr)
CA (3) CA3226155A1 (fr)
CL (3) CL2024000039A1 (fr)
CO (3) CO2024000631A2 (fr)
CR (3) CR20240064A (fr)
DK (3) DK4175620T3 (fr)
DO (3) DOP2024000004A (fr)
EC (1) ECSP24011022A (fr)
ES (3) ES2981709T3 (fr)
FI (3) FI4175620T3 (fr)
HR (3) HRP20240753T1 (fr)
HU (3) HUE067281T2 (fr)
IL (3) IL309907A (fr)
LT (3) LT4175619T (fr)
MA (3) MA61888B1 (fr)
MX (3) MX2024000467A (fr)
PE (3) PE20241067A1 (fr)
PL (3) PL4175619T3 (fr)
PT (3) PT4197528T (fr)
RS (3) RS65537B1 (fr)
SI (3) SI4175619T1 (fr)
SM (3) SMT202400368T1 (fr)
TW (3) TW202317080A (fr)
WO (3) WO2023283441A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025518628A (ja) * 2022-04-28 2025-06-18 アストラゼネカ・アクチエボラーグ 喘息の治療のための医薬組成物及び方法
CN116270464B (zh) * 2023-03-01 2025-09-30 深圳市贝美药业有限公司 一种克立硼罗气雾剂及其制备方法
FR3150798B1 (fr) 2023-07-07 2025-11-21 Aptar France Sas Dispositif de distribution de produit fluide
US12545493B2 (en) 2024-02-23 2026-02-10 Marcelo Lazaro Zelicovich Aerosol delivery system with enhanced air suspension
WO2025179179A1 (fr) * 2024-02-23 2025-08-28 Astrazeneca Ab Polythérapie à triple combinaison pour bpco
WO2026006658A1 (fr) * 2024-06-27 2026-01-02 Lupin Inc. Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
WO2026011141A1 (fr) * 2024-07-05 2026-01-08 Honeywell International Inc. Compositions, dispositifs et procédés d'administration respiratoire de principes actifs pharmaceutiques
GB202410910D0 (en) * 2024-07-25 2024-09-11 Bespak Europe Ltd Method of filling a pressurised dispensing container and filled pressurised dispensing container
US12496272B1 (en) 2024-07-31 2025-12-16 Amphastar Pharmaceuticals, Inc. Stable epinephrine suspension formulation for inhalation with HFO propellant
US12383516B1 (en) 2025-01-06 2025-08-12 Amphastar Pharmaceuticals, Inc. Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37872A (en) 1863-03-10 Improved mast-hoop
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (fr) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
JPS56138200A (en) 1980-02-15 1981-10-28 Glaxo Group Ltd Androstane carbothioate compound
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
NZ500555A (en) 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
CN1188111C (zh) 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
JP2006503961A (ja) 2002-10-25 2006-02-02 ハネウェル・インターナショナル・インコーポレーテッド ペンタフルオロプロペンに基づく組成物
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
AU2004220357B2 (en) 2003-03-10 2010-09-30 Astrazeneca Ab Novel process for the preparation of roflumilast
US7862834B2 (en) 2003-05-28 2011-01-04 Novartis Pharma Ag Pharmaceutical formulation comprising a water-insoluble active agent
US9308199B2 (en) 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
EP1904219A4 (fr) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Procede de formation de particules
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
AU2007324375A1 (en) * 2006-11-20 2008-05-29 Cipla Limited An aerosol device
EP3111926B1 (fr) 2009-05-29 2019-12-11 Pearl Therapeutics, Inc. Compositions, procédés et systèmes pour une administration respiratoire de deux ou de plusieurs agents actifs
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
UA106098C2 (uk) * 2009-12-23 2014-07-25 К'Єзі Фармачеутічі С.П.А. Аерозольна композиція для хозл
AU2011368334A1 (en) * 2011-05-17 2013-11-21 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
EP2776395A2 (fr) 2011-11-09 2014-09-17 Mylan Laboratories, Limited Procédé pour la préparation de roflumilast
CA2865972C (fr) * 2012-02-29 2022-01-04 Pulmatrix, Inc. Poudres seches pouvant etre inhalees
ES2625417T3 (es) 2012-10-17 2017-07-19 Interquim, S.A. Procedimiento para preparar roflumilast
DK2948148T3 (da) * 2013-01-28 2020-10-26 Incozen Therapeutics Pvt Ltd Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid
PE20160155A1 (es) * 2013-05-22 2016-04-01 Pearl Therapeutics Inc Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
SG11202003062QA (en) 2017-10-09 2020-04-29 Pearl Therapeutics Inc Drug delivery systems and related methods

Also Published As

Publication number Publication date
EP4175619A1 (fr) 2023-05-10
SMT202400368T1 (it) 2024-11-15
KR20240042437A (ko) 2024-04-02
FI4175620T3 (fi) 2024-06-25
CA3226557A1 (fr) 2023-01-12
MX2024000465A (es) 2024-04-05
ES2981514T3 (es) 2024-10-09
JP2024527348A (ja) 2024-07-24
RS65597B1 (sr) 2024-06-28
LT4197528T (lt) 2024-06-10
PE20240807A1 (es) 2024-04-18
US20240325298A1 (en) 2024-10-03
CL2024000037A1 (es) 2024-08-16
EP4175620B1 (fr) 2024-04-10
PT4197528T (pt) 2024-06-06
DOP2024000004A (es) 2024-04-15
JP2024525567A (ja) 2024-07-12
HRP20240716T1 (hr) 2024-08-30
SMT202400370T1 (it) 2024-11-15
CL2024000039A1 (es) 2024-08-16
IL309908A (en) 2024-03-01
EP4175620A1 (fr) 2023-05-10
PL4175620T3 (pl) 2024-08-05
PT4175619T (pt) 2024-06-06
PE20241067A1 (es) 2024-05-13
FI4197528T3 (fi) 2024-05-24
RS65537B1 (sr) 2024-06-28
IL309888A (en) 2024-03-01
JP2024525555A (ja) 2024-07-12
TW202317079A (zh) 2023-05-01
PL4175619T3 (pl) 2024-08-05
EP4393478A3 (fr) 2024-09-11
MA60224B1 (fr) 2024-06-28
SI4175619T1 (sl) 2024-08-30
CO2024000742A2 (es) 2024-02-26
HUE067547T2 (hu) 2024-10-28
HRP20240725T1 (hr) 2024-08-30
SI4197528T1 (sl) 2024-08-30
KR20240042438A (ko) 2024-04-02
EP4393477A3 (fr) 2024-09-11
CA3226155A1 (fr) 2023-01-12
HRP20240753T1 (hr) 2024-09-13
PL4197528T3 (pl) 2024-08-12
KR20240042436A (ko) 2024-04-02
US20240252440A1 (en) 2024-08-01
PT4175620T (pt) 2024-06-21
US20240358662A1 (en) 2024-10-31
MX2024000468A (es) 2024-04-05
CR20240063A (es) 2024-04-25
EP4197528B1 (fr) 2024-04-03
TW202317080A (zh) 2023-05-01
WO2023283439A1 (fr) 2023-01-12
EP4366695A1 (fr) 2024-05-15
PE20240808A1 (es) 2024-04-18
DK4175619T3 (da) 2024-05-06
CO2024000748A2 (es) 2024-02-26
US20230026203A1 (en) 2023-01-26
EP4175619B1 (fr) 2024-04-10
EP4197528A1 (fr) 2023-06-21
EP4393477A2 (fr) 2024-07-03
HUE067281T2 (hu) 2024-10-28
CR20240064A (es) 2024-09-02
DK4175620T3 (da) 2024-06-03
LT4175619T (lt) 2024-06-10
CL2024000041A1 (es) 2024-08-16
CR20240066A (es) 2024-04-12
ES2981709T3 (es) 2024-10-10
DOP2024000005A (es) 2024-04-15
DOP2024000006A (es) 2024-04-15
WO2023283438A1 (fr) 2023-01-12
ES2983201T3 (es) 2024-10-22
AU2022306682A1 (en) 2024-01-25
MX2024000467A (es) 2024-04-05
TW202317081A (zh) 2023-05-01
SMT202400312T1 (it) 2024-09-16
US20240252432A1 (en) 2024-08-01
ECSP24011022A (es) 2024-03-01
CA3226153A1 (fr) 2023-01-12
WO2023283441A1 (fr) 2023-01-12
DK4197528T3 (da) 2024-05-06
LT4175620T (lt) 2024-06-25
CO2024000631A2 (es) 2024-02-15
SI4175620T1 (sl) 2024-08-30
EP4393478A2 (fr) 2024-07-03
FI4175619T3 (fi) 2024-05-28
RS65598B1 (sr) 2024-06-28
IL309907A (en) 2024-03-01
AU2022305962A1 (en) 2024-01-25
HUE067283T2 (hu) 2024-10-28
MA60223B1 (fr) 2024-06-28
AU2022308837A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
MA61888B1 (fr) Compositions, procédés et systèmes pour l'administration de médicament en aérosol
Daley‐Yates et al. Therapeutic index of inhaled corticosteroids in asthma: A dose–response comparison on airway hyperresponsiveness and adrenal axis suppression
Tashkin et al. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
Singh et al. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
Bjermer et al. Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma
Maltais et al. A randomized, double-blind, double-dummy study of glycopyrrolate/formoterol fumarate metered dose inhaler relative to umeclidinium/vilanterol dry powder inhaler in COPD
Nathan et al. Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial
Singh et al. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
Reisner et al. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease
Rennard et al. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease
Shah et al. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers
Matera et al. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease
Beier et al. Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
Fabbri et al. Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD
Singh et al. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study
Beeh et al. Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma
Fowler et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel CRTH2 antagonist BI 1021958 at single oral doses in healthy men and multiple oral doses in men and women with well‐controlled asthma
KR20040086301A (ko) 류마티스성 관절염의 치료
Mariotti et al. A two-period open-label, single-dose crossover study in healthy volunteers to evaluate the drug–drug interaction between cimetidine and inhaled extrafine CHF 5993
Singh et al. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study
Sethi et al. Efficacy of formoterol fumarate delivered by metered dose inhaler using Co-Suspension™ Delivery Technology versus Foradil® Aerolizer® in moderate-to-severe COPD: a randomized, dose-ranging study
Miller et al. Randomized dose-ranging study of a budesonide metereddose inhaler by using co-suspension delivery technology in asthma.
Norman Developments in inhaled combination therapies: patent activity 2013–2014
AR126410A1 (es) Composiciones, métodos y sistemas para la administración de fármacos en aerosol
Gross The COPD Pipeline, XXVI